Aclaris Therapeutics Inc Receives a Buy from Jefferies

By Jason Carr

In a report released yesterday, Eun Yang from Jefferies reiterated a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS), with a price target of $36. The company’s shares closed yesterday at $24.98.

According to, Yang is a 4-star analyst with an average return of 2.9% and a 48.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Aclaris Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $43.33.

Based on Aclaris Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $12.56 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $13.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in identifying, developing and commercializing novel drugs to address unmet needs in dermatology. It also pursues the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.